Once-a-day Regimen With Everolimus, Low Dose Cyclosporine and Steroids in Comparison With Steroid Withdrawal or Twice a Day Regimen With Everolimus, Low Dose Cyclosporine and Steroids.

Model scores of the 29,894 trials active now.

Model score 16% for any early termination, 3% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 10% of the time (1,463 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2012-07-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: transplantkidneyeverolimustransplantationpatients
  Phrases that lowered it: visitdaysinglemass indexbody mass
• Accepts healthy volunteers: No (raises risk) · Who can join
• Sponsor's past termination rate: 3.9% (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 140 (lowers risk) · Sponsor's track record
• Phase: 3 (lowers risk) · Design
• Has a data monitoring committee: not given (lowers risk) · Design
• Design: parallel (raises risk) · Design
• Drug's FAERS reports with a death: 26.0% (raises risk) · Drug's FDA history
• Sponsor's past trials: 359 (lowers risk) · Sponsor's track record
• Primary purpose: prevention (lowers risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports marked serious: 95.3% (raises risk) · Drug's FDA history
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cancer: No (lowers risk) · Disease area
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Responsible party: sponsor (lowers risk) · Design
• Blinding: none (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Concentration Controlled Everolimus With Reduced Dose Cyclosporine Versus Mycophenolate Mofetil With Standard Dose Cyclosporine in de Novo Renal Transplant Adult Recipients Treated With Basiliximab and Corticosteroids NCT00658320 · started 2008 · scored riskier than 25% of active trials completed
• Role of Everolimus in Highly Sensitized Patients NCT01911546 · started 2013 · scored riskier than 99% of active trials completed
• Efficacy and Safety of Everolimus in Liver Transplant Recipients of Living Donor Liver Transplants NCT01888432 · started 2013 · scored riskier than 65% of active trials completed
• A Multicentre, Randomised, Open-label, Controlled, 12-month Follow-up Study to Assess Impact on Renal Function of an Immunosuppression Regimen Based on Tacrolimus Minimisation in Association With Everolimus in de Novo Liver Transplant Recipients. NCT02040584 · started 2013 · scored riskier than 30% of active trials completed
• REnal Function in Liver Transplantation: Everolimus With Calcineurin Inhibitor (CNI)-Sparing sTrategy NCT02115113 · started 2014 · scored riskier than 64% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.